A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover Study in Healthy Volunteers to Investigate the Effect of Oral Dosing with AZD9668 on Airway Inflammation as Assessed in Induced Sputum after Challenge with Inhaled Lipopolysaccharide (LPS).
Latest Information Update: 15 Nov 2011
At a glance
- Drugs Alvelestat (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 09 Aug 2011 New trial record